Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1038/277397a0 | DOI Listing |
JAMA Netw Open
January 2025
Department of Psychiatry, Harvard Medical School, Boston, Massachusetts.
Importance: During buprenorphine treatment for opioid use disorder (OUD), risk factors for opioid relapse or treatment dropout include comorbid substance use disorder, anxiety, or residual opioid craving. There is a need for a well-powered trial to evaluate virtually delivered groups, including both mindfulness and evidence-based approaches, to address these comorbidities during buprenorphine treatment.
Objective: To compare the effects of the Mindful Recovery Opioid Use Disorder Care Continuum (M-ROCC) vs active control among adults receiving buprenorphine for OUD.
Behav Brain Res
January 2025
Programa de Pós-Graduação em Nutrição e Saúde (PPGNS), Universidade Estadual do Ceará, CEP 60.741-000, Fortaleza-CE; Laboratório de Bioprospecção de Produtos Naturais e Biotecnologia (LBPNB), Campus CECITEC, CEP 60.660-000, Tauá-CE, Brasil. Electronic address:
Pharmacotherapy in Alcohol Withdrawal Syndrome (AWS), which is a mental disorder, generally involves benzodiazepines due to their action via GABA, but their side effects, such as excessive sedation, mental confusion and risk of dependence, are considerable. It is important to investigate the anxiolytic potential of plants such as Caryocar coriaceum, due to the presence of secondary metabolic compounds, such as isoquercitrin, capable of promoting the reduction of anxiety during AWS. We evaluated the anxiolytic-like potential of ethanolic extracts from the leaves (EEPL) and pulp (EEPP) of C.
View Article and Find Full Text PDFSpec Care Dentist
January 2025
Department of Periodontology, Faculty of Dental Medicine, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.
Aims: To assess and compare the effectiveness of pharmacological and cognitive-behavioral modalities-behavioral methods (BM), nitrous oxide inhalation sedation (NOIS), and premedication with Diazepam-for alleviating anxiety during dental treatment, using completed treatment sessions and adverse outcomes as indicators.
Methods And Results: For 239 patients (515 dental records), 18-53 y/o, who underwent dental treatments under anxiety reduction measures, sessions under NOIS were categorized as "nitrous group" (456 sessions) versus premedication with Diazepam or behavioral strategies (control, 59 sessions). Outcomes were completed treatment sessions considering demographic and clinical parameters, and adverse outcomes during and between sessions.
Harm Reduct J
January 2025
Salvation Army Centre for Addiction Services and Research, University of Stirling, Stirling, Scotland.
Background: Scotland currently has amongst the highest rates of drug-related deaths in Europe, leading to increased advocacy for safer drug consumption facilities (SDCFs) to be piloted in the country. In response to concerns about drug-related harms in Edinburgh, elected officials have considered introducing SDCFs in the city. This paper presents key findings from a feasibility study commissioned by City of Edinburgh Council to support these deliberations.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!